Article
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
BMC infectious diseases - 23 Apr 2021
Mikasi Sello Given, Isaacs Darren, Chitongo Rumbidzai, Ikomey George Mondide, Jacobs Graeme Brendon, Cloete Ruben
Abstract excerpt
BACKGROUND: The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations when compared with other class of regimens. METHODS: We evaluated the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.